Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Cartier Cuts 7.9 g/t Au Over 4.0 m Within A Broader Segment of 2.3 g/t Au Over 19.0 m at Hope Sector ; Unlocks New High-Grade Gold Zone in Underexplored Pontiac Sediments
CHARBONE annonce la signature d'un contrat d'approvisionnement de trois ans en oxygene UHP avec un client strategique americain, renforcant sa presence aux Etats-Unis
CHARBONE Announces the Signing of a Three-year UHP Oxygen Supply Contract with a Strategic American Customer, Strengthening its Presence in the United States
